Multiple sclerosis in the elderly: a retrospective cohort study.
Comorbidities
Disease-modifying therapies
Elderly
Immunosenescence
Late-onset multiple sclerosis
Multiple sclerosis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
07
07
2023
accepted:
30
09
2023
revised:
29
09
2023
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
aheadofprint
Résumé
There is a lack of knowledge of disease course, prognosis, comorbidities and potential treatments of elderly MS patients. To characterize the disease course including disability progression and relapses, to quantify the use of DMTs and to identify comorbidities and risk factors for progression in elderly multiple sclerosis (MS) patients. This is a retrospective study of 1200 Austrian MS patients older than 55 years as of May 1st, 2017 representing roughly one-third of all the MS patients of this age in Austria. Data were collected from 15 MS centers including demographics, first symptom at onset, number of relapses, evolvement of disability, medication, and comorbidities. Median observation time was 17.1 years with 957 (80%) relapsing and 243 (20%) progressive onsets. Average age at diagnosis was 45 years with a female predominance of 71%. Three-hundred and twenty-six (27%) patients were never treated with a DMT, while most treated patients received interferons (496; 41%) at some point. At last follow-up, 420 (35%) patients were still treated with a DMT. No difference was found between treated and never-treated patients in terms of clinical outcome; however, patients with worse disability progression had significantly more DMT switches. Pyramidal onset, number of comorbidities, dementia, epilepsy, and psychiatric conditions as well as a higher number of relapses were associated with worse outcome. The risk of reaching EDSS 6 rose with every additional comorbidity by 22%. In late and very-late-onset MS (LOMS, VLOMS) time to diagnosis took nearly twice the time compared to adult and early onset (AEOMS). The overall annualized relapse rate (ARR) decreased over time and patients with AEOMS had significantly higher ARR compared to LOMS and VLOMS. Four percent of MS patients had five medications or more fulfilling criteria of polypharmacy and 20% of psychiatric drugs were administered without a matching diagnosis. In this study, we identified number of comorbidities, pyramidal and cerebellar signs, and a higher number of relapses as unfavorable prognostic factors in elderly MS patients filling gaps of knowledge in patients usually underrepresented in clinical trials and may guide future therapeutic studies.
Sections du résumé
BACKGROUND
BACKGROUND
There is a lack of knowledge of disease course, prognosis, comorbidities and potential treatments of elderly MS patients.
OBJECTIVE
OBJECTIVE
To characterize the disease course including disability progression and relapses, to quantify the use of DMTs and to identify comorbidities and risk factors for progression in elderly multiple sclerosis (MS) patients.
METHODS
METHODS
This is a retrospective study of 1200 Austrian MS patients older than 55 years as of May 1st, 2017 representing roughly one-third of all the MS patients of this age in Austria. Data were collected from 15 MS centers including demographics, first symptom at onset, number of relapses, evolvement of disability, medication, and comorbidities.
RESULTS
RESULTS
Median observation time was 17.1 years with 957 (80%) relapsing and 243 (20%) progressive onsets. Average age at diagnosis was 45 years with a female predominance of 71%. Three-hundred and twenty-six (27%) patients were never treated with a DMT, while most treated patients received interferons (496; 41%) at some point. At last follow-up, 420 (35%) patients were still treated with a DMT. No difference was found between treated and never-treated patients in terms of clinical outcome; however, patients with worse disability progression had significantly more DMT switches. Pyramidal onset, number of comorbidities, dementia, epilepsy, and psychiatric conditions as well as a higher number of relapses were associated with worse outcome. The risk of reaching EDSS 6 rose with every additional comorbidity by 22%. In late and very-late-onset MS (LOMS, VLOMS) time to diagnosis took nearly twice the time compared to adult and early onset (AEOMS). The overall annualized relapse rate (ARR) decreased over time and patients with AEOMS had significantly higher ARR compared to LOMS and VLOMS. Four percent of MS patients had five medications or more fulfilling criteria of polypharmacy and 20% of psychiatric drugs were administered without a matching diagnosis.
CONCLUSIONS
CONCLUSIONS
In this study, we identified number of comorbidities, pyramidal and cerebellar signs, and a higher number of relapses as unfavorable prognostic factors in elderly MS patients filling gaps of knowledge in patients usually underrepresented in clinical trials and may guide future therapeutic studies.
Identifiants
pubmed: 37855871
doi: 10.1007/s00415-023-12041-1
pii: 10.1007/s00415-023-12041-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372(9648):1502–1517. https://doi.org/10.1016/S0140-6736(08)61620-7 . (in English)
doi: 10.1016/S0140-6736(08)61620-7
pubmed: 18970977
Tutuncu M et al (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19(2):188–198. https://doi.org/10.1177/1352458512451510 . (in English)
doi: 10.1177/1352458512451510
pubmed: 22736750
Awad A, Stüve O (2010) Multiple sclerosis in the elderly patient. Drugs Aging 27(4):283–294. https://doi.org/10.2165/11532120-000000000-00000 . (in English)
doi: 10.2165/11532120-000000000-00000
pubmed: 20359260
Buhse M (2015) The elderly person with multiple sclerosis: clinical implications for the increasing life-span. J Neurosci Nurs 47(6):333–339. https://doi.org/10.1097/JNN.0000000000000172 . (in English)
doi: 10.1097/JNN.0000000000000172
pubmed: 26528951
Scalfari A (2019) MS progression is predominantly driven by age-related mechanisms—YES. Mult Scler 25(7):902–904. https://doi.org/10.1177/1352458518820633 . (in English)
doi: 10.1177/1352458518820633
pubmed: 30747579
Kalincik T et al (2014) Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 20(11):1511–1522. https://doi.org/10.1177/1352458514528762 . (in English)
doi: 10.1177/1352458514528762
pubmed: 24777276
Ontaneda D, Fox RJ (2015) Progressive multiple sclerosis. Curr Opin Neurol 28(3):237–243. https://doi.org/10.1097/WCO.0000000000000195 . (in English)
doi: 10.1097/WCO.0000000000000195
pubmed: 25887766
pmcid: 4425257
Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017) Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 8:577. https://doi.org/10.3389/fneur.2017.00577 . (in English)
doi: 10.3389/fneur.2017.00577
pubmed: 29176956
pmcid: 5686062
Frahm N, Hecker M, Zettl UK (2019) Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. Biol Sex Differ 10(1):27. https://doi.org/10.1186/s13293-019-0243-9
doi: 10.1186/s13293-019-0243-9
pubmed: 31133051
pmcid: 6537438
Magyari M, Sorensen PS (2020) Comorbidity in multiple sclerosis. Front Neurol 11:851. https://doi.org/10.3389/fneur.2020.00851 . (in English)
doi: 10.3389/fneur.2020.00851
pubmed: 32973654
pmcid: 7473304
Musella A et al (2018) Interplay between age and neuroinflammation in multiple sclerosis: effects on motor and cognitive functions. Front Aging Neurosci 10:238. https://doi.org/10.3389/fnagi.2018.00238 . (in English)
doi: 10.3389/fnagi.2018.00238
pubmed: 30135651
pmcid: 6092506
Bolton C, Smith PA (2018) The influence and impact of ageing and immunosenescence (ISC) on adaptive immunity during multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE). Ageing Res Rev 41:64–81. https://doi.org/10.1016/j.arr.2017.10.005 . (in English)
doi: 10.1016/j.arr.2017.10.005
pubmed: 29101043
Buscarinu MC et al (2022) Late-onset MS: disease course and safety-efficacy of DMTS. Front Neurol 13:829331. https://doi.org/10.3389/fneur.2022.829331 . (in English)
doi: 10.3389/fneur.2022.829331
pubmed: 35356454
pmcid: 8960027
Mills EA, Mao-Draayer Y (2018) Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler 24(8):1014–1022. https://doi.org/10.1177/1352458518775550 . (in English)
doi: 10.1177/1352458518775550
pubmed: 29774781
pmcid: 6013383
Sanai SA et al (2016) Aging and multiple sclerosis. Mult Scler 22(6):717–725. https://doi.org/10.1177/1352458516634871 . (in English)
doi: 10.1177/1352458516634871
pubmed: 26895718
Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129(Pt 3):595–605. https://doi.org/10.1093/brain/awh714 . (in English)
doi: 10.1093/brain/awh714
pubmed: 16415309
Salhofer-Polanyi S et al (2017) Epidemiology of multiple sclerosis in Austria. Neuroepidemiology 49(1–2):40–44. https://doi.org/10.1159/000479696 . (in English)
doi: 10.1159/000479696
pubmed: 28848208
GMS Collaborators (2019) Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(3):269–285. https://doi.org/10.1016/S1474-4422(18)30443-5 . (in English)
doi: 10.1016/S1474-4422(18)30443-5
BU (2011) Multiple Sklerose, Prävalenz & Therapie im 12-Jahres-Vergleich in Österreich. https://www.msges.at/wp-content/uploads/2018/03/MS-Praevalenz-und-Therapie-2014.pdf
Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y, Neurologists U (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73(20):1616–1623. https://doi.org/10.1212/WNL.0b013e3181c1e44f . (in English)
doi: 10.1212/WNL.0b013e3181c1e44f
pubmed: 19890070
pmcid: 2881858
Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC (2013) Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol 70(2):214–222. https://doi.org/10.1001/jamaneurol.2013.599 . (in English)
doi: 10.1001/jamaneurol.2013.599
pubmed: 23407713
Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343(20):1430–1438. https://doi.org/10.1056/NEJM200011163432001 . (in English)
doi: 10.1056/NEJM200011163432001
pubmed: 11078767
Paz Soldán MM et al (2015) Relapses and disability accumulation in progressive multiple sclerosis. Neurology 84(1):81–88. https://doi.org/10.1212/WNL.0000000000001094 . (in English)
doi: 10.1212/WNL.0000000000001094
pubmed: 25398229
pmcid: 4336097
Brown MG et al (2007) How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69(15):1498–1507. https://doi.org/10.1212/01.wnl.0000271884.11129.f3 . (in English)
doi: 10.1212/01.wnl.0000271884.11129.f3
pubmed: 17699802
Amato MP et al (2020) Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 143(10):3013–3024. https://doi.org/10.1093/brain/awaa251 . (in English)
doi: 10.1093/brain/awaa251
pubmed: 32935843
Trojano M et al (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61(4):300–306. https://doi.org/10.1002/ana.21102 . (in English)
doi: 10.1002/ana.21102
pubmed: 17444502
Kappos L et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87(10):978–987. https://doi.org/10.1212/WNL.0000000000003078 . (in English)
doi: 10.1212/WNL.0000000000003078
pubmed: 27511182
pmcid: 5027814
Cree BA et al (2016) Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80(4):499–510. https://doi.org/10.1002/ana.24747 . (in English)
doi: 10.1002/ana.24747
pubmed: 27464262
pmcid: 5105678
Claflin SB, Tan B, Taylor BV (2019) The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 36:101374. https://doi.org/10.1016/j.msard.2019.08.016 . (in English)
doi: 10.1016/j.msard.2019.08.016
pubmed: 31450158
Shirani A et al (2012) Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308(3):247–256. https://doi.org/10.1001/jama.2012.7625 . (in English)
doi: 10.1001/jama.2012.7625
pubmed: 22797642
Bsteh G et al (2019) To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. Mult Scler Relat Disord 39:101908. https://doi.org/10.1016/j.msard.2019.101908 . (in English)
doi: 10.1016/j.msard.2019.101908
pubmed: 31896060
Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R (2017) Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. J Neurovirol 23(5):742–749. https://doi.org/10.1007/s13365-017-0561-9 . (in English)
doi: 10.1007/s13365-017-0561-9
pubmed: 28791614
Schweitzer F et al (2019) Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Curr Opin Neurol 32(3):305–312. https://doi.org/10.1097/WCO.0000000000000701 . (in English)
doi: 10.1097/WCO.0000000000000701
pubmed: 30985373
Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG (2019) Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler 25(5):699–708. https://doi.org/10.1177/1352458518765656 . (in English)
doi: 10.1177/1352458518765656
pubmed: 29557704
Förster M et al (2019) Managing risks with immune therapies in multiple sclerosis. Drug Saf 42(5):633–647. https://doi.org/10.1007/s40264-018-0782-8 . (in English)
doi: 10.1007/s40264-018-0782-8
pubmed: 30607830
Haselkorn JK, Loomis S (2005) Multiple sclerosis and spasticity. Phys Med Rehabil Clin N Am 16(2):467–481. https://doi.org/10.1016/j.pmr.2005.01.006 . (in English)
doi: 10.1016/j.pmr.2005.01.006
pubmed: 15893682
Bove R et al (2016) Multiple sclerosis in men: management considerations. J Neurol 263(7):1263–1273. https://doi.org/10.1007/s00415-015-8005-z . (in English)
doi: 10.1007/s00415-015-8005-z
pubmed: 26725085
Koch M, Kingwell E, Rieckmann P, Tremlett H, Neurologists UMC (2010) The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81(9):1039–1043. https://doi.org/10.1136/jnnp.2010.208173 . (in English)
doi: 10.1136/jnnp.2010.208173
pubmed: 20639385
Bisson EJ, Finlayson ML, Ekuma O, Leslie WD, Marrie RA (2019) "Multiple sclerosis is associated with low bone mineral density and osteoporosis. Neurol Clin Pract 9(5):391–399. https://doi.org/10.1212/CPJ.0000000000000669 . (in English)
doi: 10.1212/CPJ.0000000000000669
pubmed: 31750024
pmcid: 6814427
Cosman F et al (1998) Fracture history and bone loss in patients with MS. Neurology 51(4):1161–1165 (in English)
doi: 10.1212/WNL.51.4.1161
pubmed: 9781548
Ribbons KA et al (2015) Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PLoS ONE 10(6):e0122686. https://doi.org/10.1371/journal.pone.0122686 . (in English)
doi: 10.1371/journal.pone.0122686
pubmed: 26046348
pmcid: 4457630
Weinstock-Guttman B et al (2004) Risk of bone loss in men with multiple sclerosis. Mult Scler 10(2):170–175. https://doi.org/10.1191/1352458504ms993oa . (in English)
doi: 10.1191/1352458504ms993oa
pubmed: 15124763
Zikán V et al (2012) Bone mineral density and body composition in men with multiple sclerosis chronically treated with low-dose glucocorticoids. Physiol Res 61(4):405–417. https://doi.org/10.33549/physiolres.932299 . (in English)
doi: 10.33549/physiolres.932299
pubmed: 22670701
Peterson EW, Cho CC, von Koch L, Finlayson ML (2008) Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 89(6):1031–1037. https://doi.org/10.1016/j.apmr.2007.10.043 . (in English)
doi: 10.1016/j.apmr.2007.10.043
pubmed: 18503796
Gibson JC, Summers GD (2011) Bone health in multiple sclerosis. Osteoporos Int 22(12):2935–2949. https://doi.org/10.1007/s00198-011-1644-8 . (in English)
doi: 10.1007/s00198-011-1644-8
pubmed: 21604009
Åivo J, Kurki S, Sumelahti ML, Hänninen K, Ruutiainen J, Soilu-Hänninen M (2017) Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland. Acta Neurol Scand 135(5):516–521. https://doi.org/10.1111/ane.12623 . (in English)
doi: 10.1111/ane.12623
pubmed: 27334254
Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41(5):685–691. https://doi.org/10.1212/wnl.41.5.685 . (in English)
doi: 10.1212/wnl.41.5.685
pubmed: 2027484
Rocca MA et al (2015) Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 14(3):302–317. https://doi.org/10.1016/S1474-4422(14)70250-9 . (in English)
doi: 10.1016/S1474-4422(14)70250-9
pubmed: 25662900
Peyser JM, Rao SM, LaRocca NG, Kaplan E (1990) Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol 47(1):94–97. https://doi.org/10.1001/archneur.1990.00530010120030 . (in English)
doi: 10.1001/archneur.1990.00530010120030
pubmed: 2403789
Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12(4):549–558. https://doi.org/10.1017/s1355617706060723 . (in English)
doi: 10.1017/s1355617706060723
pubmed: 16981607
Jakimovski D et al (2019) Cognitive profiles of aging in multiple sclerosis. Front Aging Neurosci 11:105. https://doi.org/10.3389/fnagi.2019.00105 . (in English)
doi: 10.3389/fnagi.2019.00105
pubmed: 31133845
pmcid: 6524468
Westervelt HJ (2015) Dementia in multiple sclerosis: why is it rarely discussed? Arch Clin Neuropsychol 30(2):174–177. https://doi.org/10.1093/arclin/acu095 . (in English)
doi: 10.1093/arclin/acu095
pubmed: 25618134
Bsteh G et al (2016) Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study. PLoS ONE 11(7):e0158978. https://doi.org/10.1371/journal.pone.0158978 . (in English)
doi: 10.1371/journal.pone.0158978
pubmed: 27391947
pmcid: 4938610
Hauer L, Perneczky J, Sellner J (2021) A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. J Neurol 268(11):4066–4077. https://doi.org/10.1007/s00415-020-10107-y . (in English)
doi: 10.1007/s00415-020-10107-y
pubmed: 32719975
Marrie RA et al (2010) Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 74(13):1041–1047. https://doi.org/10.1212/WNL.0b013e3181d6b125 . (in English)
doi: 10.1212/WNL.0b013e3181d6b125
pubmed: 20350978
pmcid: 2848107
Weinstock-Guttman B et al (2011) Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 8:127. https://doi.org/10.1186/1742-2094-8-127 . (in English)
doi: 10.1186/1742-2094-8-127
pubmed: 21970791
pmcid: 3228782
Tettey P et al (2016) Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology 46(2):106–113. https://doi.org/10.1159/000442203 . (in English)
doi: 10.1159/000442203
pubmed: 26784322
Salter A, Kowalec K, Fitzgerald KC, Cutter G, Marrie RA (2020) Comorbidity is associated with disease activity in MS: findings from the CombiRx trial. Neurology 95(5):e446–e456. https://doi.org/10.1212/WNL.0000000000010024 . (in English)
doi: 10.1212/WNL.0000000000010024
pubmed: 32554770
pmcid: 9629214
Giesser BS (2015) Exercise in the management of persons with multiple sclerosis. Ther Adv Neurol Disord 8(3):123–130. https://doi.org/10.1177/1756285615576663 . (in English)
doi: 10.1177/1756285615576663
pubmed: 25941539
pmcid: 4409551
Nasrallah IM et al (2019) Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA 322(6):524–534. https://doi.org/10.1001/jama.2019.10551 . (in English)
doi: 10.1001/jama.2019.10551
pubmed: 31408137
pmcid: 6692679
Ziemssen T (2009) Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 277(Suppl 1):S37-41. https://doi.org/10.1016/S0022-510X(09)70011-5 . (in English)
doi: 10.1016/S0022-510X(09)70011-5
pubmed: 19200865
Negrotto L, Farez MF, Correale J (2016) Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol 73(5):520–528. https://doi.org/10.1001/jamaneurol.2015.4807 . (in English)
doi: 10.1001/jamaneurol.2015.4807
pubmed: 26953870
Marrie RA, Horwitz RI (2010) Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 9(8):820–828. https://doi.org/10.1016/S1474-4422(10)70135-6 . (in English)
doi: 10.1016/S1474-4422(10)70135-6
pubmed: 20650403
McGinley MP, Cohen JA (2021) Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 398(10306):1184–1194. https://doi.org/10.1016/S0140-6736(21)00244-0 . (in English)
doi: 10.1016/S0140-6736(21)00244-0
pubmed: 34175020
Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F (2005) The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 11(2):175–181. https://doi.org/10.1191/1352458505ms1144oa . (in English)
doi: 10.1191/1352458505ms1144oa
pubmed: 15794391
Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN (2008) Polypharmacy: misleading, but manageable. Clin Interv Aging 3(2):383–389. https://doi.org/10.2147/cia.s2468 . (in English)
doi: 10.2147/cia.s2468
pubmed: 18686760
pmcid: 2546482
Beiske GA, Holmøy T, Beiske AG, Johannessen SI, Landmark CJ (2015) Antiepileptic and antidepressive polypharmacy in patients with multiple sclerosis. Mult Scler Int 2015:317859. https://doi.org/10.1155/2015/317859 . (in English)
doi: 10.1155/2015/317859
pubmed: 26221541
pmcid: 4499608
Morrow SA, Rosehart H, Sener A, Welk B (2018) Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis. J Neurol Sci 385:39–44. https://doi.org/10.1016/j.jns.2017.11.028 . (in English)
doi: 10.1016/j.jns.2017.11.028
pubmed: 29406911
Thelen JM, Lynch SG, Bruce AS, Hancock LM, Bruce JM (2014) Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance. J Psychosom Res 76(5):400–404. https://doi.org/10.1016/j.jpsychores.2014.02.013 . (in English)
doi: 10.1016/j.jpsychores.2014.02.013
pubmed: 24745782
Thelen J, Zvonarev V, Lam S, Burkhardt C, Lynch S, Bruce J (2021) Polypharmacy in multiple sclerosis: current knowledge and future directions. Mo Med 118(3):239–245 (in English)
pubmed: 34149084
pmcid: 8210980